Guggenheim analyst Yatin Suneja initiated coverage of Cabaletta Bio with a Buy rating and $34 price target. The firm has a positive view of CD19 CAR-T cell therapy CABA-201, which is currently in development for lupus and myositis, telling investors that its review of Cabaletta’s current approach suggests that CABA-201 is “built for I&I” and that CD19 CAR-T therapies can lead to long-lasting disease remission across multiple immunological disorders.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CABA: